Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Thoracic Malignancies
•
Medical Oncology
•
Immunotherapy
•
General Internal Medicine
Do patients with a positive antinuclear antibody (ANA) but no known diagnosis of autoimmune disease have an increased risk for toxicity from immunotherapy?
Related Questions
How, if at all, are you modifying your practice and clinical workflow for patients receiving checkpoint inhibitors with data showing improved outcomes for patients receiving infusions earlier in the day?
In stage IV oligometastatic NSCLC, when considering local consolidative therapies to the primary tumor, do providers typically stage the mediastinum at diagnosis or after initial systemic therapy (assuming no progression)?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
How do you approach stage IIa squamous cell carcinoma of the lung with a PD-L1 level of 1-49% and no targetable mutations?
How would you manage a patient who developed stage III melanoma while receiving cemiplimab (cycle 10) for locally advanced cutaneous squamous cell carcinoma?
How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?
What factors should be considered when deciding whether to omit radiation in pediatric/AYA patients receiving N+AVD, particularly regarding long-term outcomes and second malignancy risks?
How do you approach restarting immunotherapy in a patient with metastatic melanoma who previously developed immune-mediated hepatitis (Grade 3), with liver enzymes now back to baseline levels?
How does metaplastic thymoma histology impact your decision regarding adjuvant radiation?
Do patients with central adrenal insufficiency on maintenance hydrocortisone therapy require doubling of their corticosteroid during chemotherapy cycles?
